Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 26, 2026
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding Sefaxersen (Detailed Interim Analysis Data from the Phase III IMAgINATION Study)
TOKYO, October 26, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release on October 23, regarding the presentation of detailed interim analysis data from the global Phase III IMAgINATION study evaluating sefaxersen in IgA nephropathy at the American Society of Nephrology (ASN) Kidney Week 2026.
Please refer to the link below for details of Roche’s media release:
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Naoki Kouzai
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp